The treatment of venous leg ulcers: A new therapeutic use of iloprost

Annals of Surgery

Volumn 246, Issue 5, 2007, Pages 860-865

  Ferrara, Filippo ^a   Meli, Francesco ^a   Raimondi, Francesco ^a   Amato, Corrado ^a   Bonura, Francesca ^a   Mulè, Giuseppe ^a   Novo, Giuseppina ^a   Novo S, Salvatore ^a  

^a UNIVERSITY OF PALERMO   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ILOPROST; PLACEBO; SODIUM CHLORIDE;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; FEMALE; HUMAN; LEG ULCER; LOCAL THERAPY; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SCAR FORMATION; SINGLE BLIND PROCEDURE; STATISTICAL ANALYSIS; ULCER HEALING;

ANTI-INFECTIVE AGENTS, LOCAL; COMBINED MODALITY THERAPY; DEBRIDEMENT; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; ILOPROST; INFUSIONS, INTRAVENOUS; LEG ULCER; MALE; MIDDLE AGED; PLATELET AGGREGATION INHIBITORS; SINGLE-BLIND METHOD; STOCKINGS, COMPRESSION; TREATMENT OUTCOME;

EID: 35648947844     PISSN: 00034932     EISSN: None     Source Type: Journal    
DOI: 10.1097/SLA.0b013e3180caa44c     Document Type: Article

References (37)

1. Homans J. The etiology and treatment of varicose ulcer of the leg. Surg Gynecol Obstet. 1917;24:300-311.
2. Coleridge Smith PD. The drug treatment of chronic venous insufficiency and venous ulcerations. In: Gloviczky P, Yao ST, eds. Handbook of Venous Disorders. Guidelines of the American Venous Forum. London: Arnold; 2001:309-321.
3. Cheatle TR, McMullin GM, Farrah J, et al. Three tests of microcirculatory function in the evaluation of treatment for chronic venous insufficiency - a review. Phlebology. 1990;5:165-172.
4. Marschel P, Schmid-Schonbein GW. Control of fluid shear response in circulating leucocytes by integrins. Ann Biomed Eng. 2002;30:333-343.
5. Moazzam F, delano FA, Zweifach BW, et al. The leucocyte response to fluid stress. Proc Natl Acad Sci USA. 1997;94:5338-5343.
6. Peshen M, Lahaye T, Henning B, et al. Expression of the adhesion molecules ICAM-1 V-CAM1, LFA-1 and VLA-4 in the skin is modulated in progressing stages of chronic venous insufficiency. Acta Derm Venereol (Stockh). 1999;79:27-32.
7. Caimi G, Canino B, Ferrara F, et al. Polymorphonuclear leukocyte integrin in deep venous thrombosis. Clin Appl Thromb Hemost. 2005;11:95-97.
8. Coleridge Smith PD. Leg ulcers: biochemical factors. Phlebology. 2000;15:156-161.
9. Kim I, Moon SO, Kim SH, et al. Vascular endothelial growth factor expression of intercellular adhesion molecule 1 (ICAM-1), vascular cell adhesion molecule-1 (VCAM-1), and E-selectin through nuclear factor-kappa B activation in endothelial cells. J Biol Chem. 2000;278:614-7620.
10. Murphy MA, Joyce WP, Condron C, et al. A reduction in serum cytokine levels parallels healing of venous ulcers in patients undergoing compression therapy. Eur J Vasc Endovasc Surg. 2002;23:349-352.
11. Leu AJ, Leu HJ, Franzeck UK, et al. Microvascular changes in chronic venous insufficiency - a review. Cardiovasc Surg. 1995;3:237-245.
12. Thomas PRS, Nash GB, Dormandy JA. White cell accumulation in the dependent legs of patients with venous hypertension: a possible mechanism for trophic changes in the skin. BMJ. 1988;296:1693-1695.
13. Guillet G, Garcia C, Sassolas B, et al. Antiendothelial cell antibodies in chronic leg ulcers: prevalence and significance. Ann Dermatol Veneoreol. 2001;128:1301-1304.
14. Della Bella S, Molteni M, Mocellin C, et al. Novel mode of action of iloprost: in vitro down-regulation of endothelial cell adhesion molecules. Prostaglandins. 2001;65:73-83.
15. Mazzone A, Faggioli P, Cusa C, et al. Effects of iloprost on adhesion molecules and F1 + 2 in peripheral ischemia. Eur J Clin Invest. 2002;32:882-888.
16. Di Renzo M, Pieragalli D, Meini S, et al. Iloprost treatment reduces TNF-alpha production and TNF-RII expression in critical limb ischemia patients without affecting IL6. Prostaglandins Leukot Essent Fatty Acids. 2005;73:405-410.
17. Czelick EG, Simm A, Grond S, et al. Inhibition of intracellular tumor necrosis factor (TNF)-alpha and interleukin (IL)-6 production in human monocytes by iloprost. Eur J Clin Invest. 2003;33:1013-1017.
18. Werner-Schlenzka H, Kuhlmann RK. Treatment of venous leg ulcers with topical iloprost: a placebo controlled study. VASA. 1994;23:145-150.
19. Italian College of Phlebology. Guidelines for the diagnosis and therapy of the vein and lymphatic disorders. Int Angiol. 2005;24:107-68.
20. Forconi S, Jageneau A, Guerrini M, et al. Strain gauge pletismography in the study of the circulation of the limbs. Angiology. 1979;30:487.
21. Eklof B, Rutherford RB, Bergan JJ, et al.; American Venous Forum International Ad Hoc Committee for Revision of CEAP Classification. Revision of CEAP classification for chronic venous disorders: consensus statement. J Vasc Surg. 2004;40:1248-1252.
22. Lagattola N, Burnard K. Duplex ultrasonography for assessment of venous valvular function of the lower limb. Br J Surg. 1995;82:855-856.
23. Baumgartner I, Braunschweig M, Triller J, et al. Power-based colour coded duplex sonography for evaluation of calf veins. Int Angiol. 1998;17:43-48.
24. TASC Transatlantic intersociety consensus on management of peripheral arterial disease. J Vasc Surg. 2000;31:1-296.
25. Rutherford RB, Padberg FT Jr, Camerota AJ, et al. Venous severity score: An adjunct to venous outcome assessment. J Vasc Surg. 2000;31:1307-12.
26. Krause W, Krais T. Pharmacokinetics and pharmacodynamics of the prostacyclin analogue iloprost in man. Eur J Clin Pharmacol. 1985;30:61-8.
27. Riva CM, Morganroth ML, Ljungman AG, et al. Iloprost inhibits neutrophil-induced lung injury and neutrophil adherence to endothelial monolayers. Am J Respir Cell Mol Biol. 1990;3:301-309.
28. Lindeman S, Gierer C, Darius H. Prostacyclin inhibits adhesion of polymorphonuclear leukocytes to human vascular endothelial cells due to adhesion molecule independent regulatory mechanisms. Basic Res Cardiol. 2003;98:8-15.
29. Thomson IA, Egginton S, Hudlicka O, et al. Iloprost reduces leukocyte adhesion in skeletal muscle venules following ischemia in a rat model of femorodistal bypass. Eur J Vasc Endovasc Surg. 1996;11:335-341.
30. Darius H, Veit K, Binz C, et al. Diminished inhibition of adhesion molecule expression in prostacyclin receptor desensitized human platelets. Agents Actions Suppl. 1995;45:77-83.
31. Arosio E, Minuz P, Prior M, et al. Vascular adhesion molecole-1 and markers of platelet function before and after a treatment with iloprost or a supervised physical exercise program in patients with peripheral arterial disease. Life Sci. 2001;421-433.
32. Mittag M, Beckheinrich P, Haustein UF. Systemic sclerosis-related Raynaud's phenomenon: effects of iloprost infusion therapy on serum cytokine, growth factor and soluble adhesion molecule levels. Acta Derm Veneorol. 2001;81:294-297.
33. Erlansson M, Bergqvist D, Persson NH, et al. Modification of postischemic increase of leukocyte adhesion and vascular permeability in the hamster by iloprost. Prostaglandins. 1991;41:157-168.
34. Olin JW, Childs MB, McHugh L. Medical costs of treating venous stasis ulcers: evidence from a retrospective cohort study. Vasc Med. 1999;4:1-7.
35. Levy E. Medico-economic study of the management of leg ulcers of venous origin: Initial results. J Mal Vasc. 1998;23:277-281.
36. Ragnarson Tennvall G, Hjelmgren J. Treatment of venous leg ulcers is costly for the health care and the society. The value of preventive measures should be further investigated according to a study. Lakartidningen. 2005;102:3027-3029.
37. Ragnarson Tennvall G, Hjlmgren J. Annual costs of treatment for venous leg ulcers in Sweden and the United Kingdom. Wound Repair Regen. 2005;13:13-18.